BAKER BROS. ADVISORS LP
An institutional investment manager in NEW YORK, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1263508.
- Reported value$19.96bn
- Positions84
Holdings: 84 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Incyte CorporationINCY | COM | 45337C102 | 3,487 | 17.5% | 30,762,330 | Added+17,918 | |
| BeOne Medicines Ltd.ONC | SPONSORED ADS | 07725L102 | 2,508 | 12.6% | 8,801,567 | Added+2,514 | |
| Revolution Medicines, Inc.RVMD | COM | 76155X100 | 2,143 | 10.7% | 11,443,357 | Added+1,888,000 | |
| Madrigal Pharmaceuticals, Inc.MDGL | COM | 558868105 | 1,151 | 5.8% | 2,143,131 | Added+1,430 | |
| ACADIA Pharmaceuticals Inc.ACAD | COM | 004225108 | 1,086 | 5.4% | 42,912,904 | Added+16,214 | |
| Kymera Therapeutics, Inc.KYMR | COM | 501575104 | 993 | 5.0% | 8,657,242 | Unchanged | |
| Insmed IncorporatedINSM | COM PAR $.01 | 457669307 | 938 | 4.7% | 8,796,111 | Added+1,375,000 | |
| Celcuity Inc.CELC | COM | 15102K100 | 828 | 4.2% | 7,915,792 | Unchanged | |
| Kodiak Sciences Inc.KOD | COM | 50015M109 | 776 | 3.9% | 19,919,186 | Unchanged | |
| Rhythm Pharmaceuticals, Inc.RYTM | COM | 76243J105 | 622 | 3.1% | 5,604,483 | Unchanged | |
| Praxis Precision Medicines, Inc.PRAX | COM | 74006W207 | 587 | 2.9% | 1,753,198 | Unchanged | |
| Alkermes plc | SHS | G01767105 | 525 | 2.6% | 10,012,267 | Unchanged | |
| Summit Therapeutics Inc.SMMT | COM | 86627T108 | 478 | 2.4% | 32,786,348 | Reduced−3,604,715 | |
| GRAIL, Inc.GRAL | COM | 384747101 | 275 | 1.4% | 4,028,614 | Unchanged | |
| AbCellera Biologics Inc.ABCL | COM | 00288U106 | 259 | 1.3% | 33,012,138 | Added+2,736,200 | |
| Immunovant, Inc.IMVT | COM | 45258J102 | 209 | 1.0% | 5,435,220 | Reduced−22,661 | |
| IDEAYA Biosciences, Inc.IDYA | COM | 45166A102 | 187 | 0.9% | 5,010,030 | Added+1,063,515 | |
| Kiniksa Pharmaceuticals International, plc | ORD SHS CL A | G52694109 | 181 | 0.9% | 2,834,643 | Added+8,397 | |
| Roivant Sciences Ltd. | SHS | G76279101 | 167 | 0.8% | 4,716,831 | Reduced−150,892 | |
| Arrowhead Pharmaceuticals, Inc.ARWR | COM | 04280A100 | 162 | 0.8% | 1,992,783 | Unchanged | |
| Ionis Pharmaceuticals, Inc.IONS | COM | 462222100 | 162 | 0.8% | 2,047,727 | Unchanged | |
| Edgewise Therapeutics, Inc.EWTX | COM | 28036F105 | 150 | 0.8% | 3,701,719 | Reduced−2,874,221 | |
| Replimune Group, Inc.REPL | COM | 76029N106 | 122 | 0.6% | 11,045,336 | Unchanged | |
| Nurix Therapeutics, Inc.NRIX | COM | 67080M103 | 113 | 0.6% | 4,658,556 | Unchanged | |
| Stoke Therapeutics, Inc.STOK | COM | 86150R107 | 109 | 0.5% | 3,336,697 | Unchanged | |
| Monte Rosa Therapeutics, Inc.GLUE | COM | 61225M102 | 105 | 0.5% | 4,345,736 | Unchanged | |
| Immatics N.V. | SHS | N44445109 | 96.3 | 0.5% | 9,508,565 | Reduced−1,408,128 | |
| Denali Therapeutics Inc.DNLI | COM | 24823R105 | 96.0 | 0.5% | 3,734,336 | Added+2,641 | |
| Crinetics Pharmaceuticals, Inc. | COM | 22663K107 | 88.0 | 0.4% | 2,351,465 | Unchanged | |
| Dianthus Therapeutics, Inc.DNTH | COM | 252828108 | 83.1 | 0.4% | 852,164 | Unchanged | |
| Structure Therapeutics Inc.GPCR | SPONSORED ADS | 86366E106 | 76.9 | 0.4% | 1,432,529 | Unchanged | |
| Celcuity Inc. | Note 2.75% 8/1/2031 | 15102KAA8 | 69.2 | 0.3% | $30,750,000 principal | New+30,750,000 | |
| Rapport Therapeutics, Inc.RAPP | COM | 75383L102 | 64.5 | 0.3% | 1,547,090 | Unchanged | |
| Alumis Inc.ALMS | COM | 022307102 | 56.6 | 0.3% | 2,012,500 | Unchanged | |
| Prelude Therapeutics Inc.PRLD | COM | 74065P101 | 54.0 | 0.3% | 10,123,824 | Unchanged | |
| Relay Therapeutics, Inc.RLAY | COM | 75943R102 | 52.9 | 0.3% | 2,826,783 | Added+1,666,666 | |
| Mirum Pharmaceuticals, Inc.MIRM | COM | 604749101 | 52.2 | 0.3% | 445,975 | Unchanged | |
| Bicycle Therapeutics plcBCYC | SPONSORED ADS | 088786108 | 46.2 | 0.2% | 10,885,357 | Unchanged | |
| Enliven Therapeutics, Inc.ELVN | COM | 29337E102 | 45.9 | 0.2% | 905,191 | Unchanged | |
| Celldex Therapeutics, Inc.CLDX | COM | 15117B202 | 44.0 | 0.2% | 1,182,611 | Added+517,241 | |
| Viridian Therapeutics, Inc.VRDN | COM | 92790C104 | 43.8 | 0.2% | 2,383,025 | Added+411,347 | |
| Design Therapeutics, Inc.DSGN | COM | 25056L103 | 38.8 | 0.2% | 2,678,430 | Added+92,452 | |
| Entrada Therapeutics, Inc.TRDA | COM | 29384C108 | 37.3 | 0.2% | 5,072,730 | Unchanged | |
| Faeth Therapeutics, Inc.FTH | COM | 81728A207 | 32.2 | 0.2% | 1,286,411 | New+1,286,411 | |
| Aktis Oncology, Inc.AKTS | COM | 01021M104 | 32.1 | 0.2% | 996,351 | Unchanged | |
| Neurogene Inc.NGNE | COM | 64135M105 | 31.2 | 0.2% | 991,691 | Unchanged | |
| Jade Biosciences, Inc.JBIO | COM | 008064206 | 27.3 | 0.1% | 1,230,426 | Reduced−410,711 | |
| Taysha Gene Therapies, Inc.TSHA | COM SHS | 877619106 | 27.3 | 0.1% | 4,004,756 | Unchanged | |
| Arcus Biosciences, Inc.RCUS | COM | 03969F109 | 26.0 | 0.1% | 844,816 | Added+429,195 | |
| Disc Medicine, Inc.IRON | COM | 254604101 | 25.6 | 0.1% | 349,657 | Unchanged | |
| Absci CorporationABSI | COM | 00091E109 | 24.7 | 0.1% | 2,134,803 | Unchanged | |
| Generate Biomedicines, Inc.GENB | COM SHS | 370920100 | 24.0 | 0.1% | 1,423,602 | Unchanged | |
| DBV Technologies S.A.DBVT | SPONSORED ADS | 23306J309 | 24.0 | 0.1% | 1,461,425 | Unchanged | |
| Xenon Pharmaceuticals Inc.XENE | COM | 98420N105 | 22.3 | 0.1% | 370,208 | Unchanged | |
| Tectonic Therapeutic, Inc.TECX | COM | 878972108 | 20.9 | 0.1% | 607,788 | Unchanged | |
| Cerus CorporationCERS | COM | 157085101 | 18.7 | <0.1% | 6,395,431 | Reduced−3,612,914 | |
| CytomX Therapeutics, Inc.CTMX | COM | 23284F105 | 18.7 | <0.1% | 4,975,826 | Unchanged | |
| Dyne Therapeutics, Inc.DYN | COM | 26818M108 | 18.1 | <0.1% | 813,449 | Unchanged | |
| Cytokinetics, IncorporatedCYTK | COM | 23282W605 | 18.0 | <0.1% | 211,267 | New+211,267 | |
| Xencor, Inc.XNCR | COM | 98401F105 | 17.7 | <0.1% | 1,102,106 | Unchanged | |
| Sionna Therapeutics, Inc.SION | COM | 829401108 | 17.6 | <0.1% | 400,000 | Unchanged | |
| Intellia Therapeutics, Inc.NTLA | COM | 45826J105 | 15.7 | <0.1% | 930,232 | New+930,232 | |
| Parabilis Medicines, Inc.PBLS | COM | 698955101 | 13.7 | <0.1% | 500,000 | New+500,000 | |
| MapLight Therapeutics, Inc.MPLT | COM | 56565P103 | 13.1 | <0.1% | 364,705 | Unchanged | |
| Avalyn Pharma Inc.AVLN | COM SHS | 05348Y105 | 11.5 | <0.1% | 350,000 | New+350,000 | |
| Evommune, Inc.EVMN | COM SHS | 30054Y107 | 11.3 | <0.1% | 847,390 | Unchanged | |
| BioNTech SEBNTX | SPONSORED ADS | 09075V102 | 11.1 | <0.1% | 119,743 | Unchanged | |
| Tango Therapeutics, Inc.TNGX | COM | 87583X109 | 10.4 | <0.1% | 333,333 | New+333,333 | |
| Avalo Therapeutics, Inc.AVTX | COM | 05338F306 | 10.2 | <0.1% | 550,000 | New+550,000 | |
| Sera Prognostics, Inc.SERA | CLASS A COM | 81749D107 | 10.0 | <0.1% | 5,498,170 | Unchanged | |
| Verastem, Inc.VSTM | COM | 92337C203 | 9.5 | <0.1% | 2,499,338 | Added+1,914,581 | |
| Sagimet Biosciences Inc.SGMT | COM SER A | 786700104 | 7.4 | <0.1% | 952,996 | Unchanged | |
| Eikon Therapeutics, Inc.EIKN | COM | 282564103 | 7.2 | <0.1% | 555,555 | Unchanged | |
| LB Pharmaceuticals Inc.LBRX | COM SHS | 50180M108 | 6.5 | <0.1% | 200,000 | Unchanged | |
| vTv Therapeutics, Inc.VTVT | CL A | 918385204 | 5.6 | <0.1% | 148,314 | Unchanged | |
| Wave Life Sciences Ltd. | SHS | Y95308105 | 4.8 | <0.1% | 822,638 | Unchanged | |
| Protara Therapeutics, Inc.TARA | COM STK | 74365U107 | 3.7 | <0.1% | 971,614 | Unchanged | |
| TScan Therapeutics, Inc.TCRX | COM | 89854M101 | 2.7 | <0.1% | 2,784,792 | Unchanged | |
| Immunome, Inc.IMNM | COM | 45257U108 | 1.2 | <0.1% | 55,306 | New+55,306 | |
| Skye Bioscience, Inc. | COM | 83086J200 | 1.1 | <0.1% | 1,575,243 | Unchanged | |
| Sana Biotechnology, Inc.SANA | COM | 799566104 | 1.1 | <0.1% | 310,483 | Unchanged | |
| Aligos Therapeutics, Inc.ALGS | COM | 01626L204 | 0.5 | <0.1% | 83,055 | Unchanged | |
| Tyra Biosciences, Inc.TYRA | COM | 90240B106 | 0.3 | <0.1% | 10,607 | Unchanged | |
| Surrozen, Inc. Warrants @ $172.50 8/11/2026 (15 FOR 1) | W EXP 8/11/2026 | 86889P117 | 0.0 | <0.1% | 833,333 | Unchanged |
Sold out: 9 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Abivax S.A.ABVX | SPONSORED ADS | 00370M103 | 0.0 | 0.0% | 0 | Sold out−875,796 | |
| argenx SEARGX | SPONSORED ADR | 04016X101 | 0.0 | 0.0% | 0 | Sold out−25,174 | |
| Celcuity Inc. | Note 2.75% 8/1/2031 | 15102KAA8 | 0.0 | 0.0% | 0 | Sold out−30,750,000 | |
| Centessa Pharmaceuticals plc | SPONSORED ADS | 152309100 | 0.0 | 0.0% | 0 | Sold out−670,751 | |
| COMPASS Pathways plcCMPS | SPONSORED ADS | 20451W101 | 0.0 | 0.0% | 0 | Sold out−2,344,720 | |
| Contineum Therapeutics, Inc.CTNM | CL A | 21217B100 | 0.0 | 0.0% | 0 | Sold out−1,420,838 | |
| Immunocore Holdings plcIMCR | ADS | 45258D105 | 0.0 | 0.0% | 0 | Sold out−734,397 | |
| Pharvaris N.V. | COM | N69605108 | 0.0 | 0.0% | 0 | Sold out−375,000 | |
| Spyre Therapeutics, Inc.SYRE | COM | 00773J202 | 0.0 | 0.0% | 0 | Sold out−1,000,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-097191 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.